Baird analyst Ben Kallo maintains First Solar (NASDAQ:FSLR) with a Outperform and raises the price target from $180 to $208.
Tarsus To Present Saturn-2 Pivotal Phase 3 Trial Data And Saturn-1 Extension Study Long-term Safety Data Evaluating TP-03 For The Treatment Of Demodex Blepharitis At Upcoming Eye Care Meetings
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that the
